This was most interesting: "multiple secondary endpoints will be studied..."

Makes me wonder if psoriatic arthritis is involved in this. Maybe some of the people who took Prurisol had psoriatic arthritis which improved? Or maybe they will be enrolling patients in the next phase who have psoriatic arthritis to see what happens?

Anybody got any ideas about this?